# RASGRP1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - RASGRP1 functions as a guanine nucleotide exchange factor (GEF) for Ras GTPases, critically mediating signal transduction from antigen receptors, growth factor receptors, and cytokine receptors to downstream MAPK cascades, essential for cellular proliferation, differentiation, and survival. - Loss-of-function mutations in *RASGRP1* lead to combined immunodeficiency (CID) and autoimmune lymphoproliferative syndrome (ALPS)-like disease, characterized by recurrent infections, autoimmunity, and increased lymphoma risk due to impaired T and B cell signaling. - Overexpression of RASGRP1 is an oncogenic driver in T-cell acute lymphoblastic leukemia (T-ALL), promoting leukemic cell survival and proliferation by enhancing cytokine-driven Ras/PI3K/Akt signaling. - Genetic variants in *RASGRP1* are associated with susceptibility to complex diseases including type 1 and type 2 diabetes, systemic lupus erythematosus (SLE), and schizophrenia, indicating its broad role in immune homeostasis and neurological function. - RASGRP1's activity is tightly regulated by membrane recruitment via its C1 domain (DAG binding) and calcium sensing through EF-hand motifs, with post-translational modifications like farnesylation being crucial for its function and a target for inhibitors like tipifarnib. - Alternative splicing, particularly involving exon 11, generates functional isoforms of RASGRP1, and dysregulation of this process, as seen in SLE due to reduced SRSF1, contributes to disease pathogenesis by altering protein levels and activity. --- ## Executive Summary & Key Metadata RAS guanyl-releasing protein 1 (RASGRP1) is a 797-amino acid, ~90 kDa intracellular signaling protein that functions as a guanine nucleotide exchange factor (GEF) for Ras family small GTPases [1]. The protein is a critical node in the relay of signals from antigen receptors, growth factor receptors, and cytokine receptors to downstream mitogen-activated protein kinase (MAPK) cascades. Its expression and activity are tightly regulated in a cell-type and developmental-stage-specific manner, and dysregulation—whether through loss-of-function mutations, aberrant overexpression, or altered splicing—is associated with a spectrum of human pathologies, including primary immunodeficiencies, autoimmunity, leukemia, and lymphoma. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | RASGRP1 | | **UniProt Accession** | O95267 | | **Representative PDB ID** | true (Multiple domain structures available; see Section 2) | | **Chromosomal Locus** | 15q14 (GRCh38: chr15:38,488,144-38,564,319) | | **Primary Molecular Function** | Ras guanine nucleotide exchange factor (RasGEF); converts inactive Ras-GDP to active Ras-GTP | | **Disease & Pathology Associations** | Combined immunodeficiency (CID), autoimmune lymphoproliferative syndrome (ALPS)-like disease, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), T-cell acute lymphoblastic leukemia (T-ALL), psoriasis, schizophrenia, type 1/type 2 diabetes | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The *RASGRP1* gene is located on the long arm of human chromosome 15 at cytogenetic band 15q14. The gene spans approximately 76 kilobases (kb) of genomic DNA on the plus strand. The reference genome assembly (GRCh38) places the gene between genomic coordinates 38,488,144 and 38,564,319. The locus is gene-dense, with neighboring genes including *APTX* (aprataxin) and *SPPL2A* (signal peptide peptidase-like 2A). The proximity of *RASGRP1* to *APTX* is of clinical interest, as the expression ratio of these two genes has been investigated as a predictive biomarker for response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia (AML) [2, 3, 4]. The gene consists of 17 primary exons, with the translational start site located in exon 1 and the stop codon in exon 17. The exon-intron architecture is complex, with alternative splicing events generating multiple transcript variants. The canonical transcript (ENST00000268121.9) encodes the full-length 797-amino acid protein. However, several alternatively spliced isoforms have been documented, particularly involving exon 11, which encodes a portion of the Ras exchange motif (REM) domain [5]. ### 1.2 Promoter Architecture and Transcriptional Regulation The *RASGRP1* promoter region lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island is a target for DNA methylation-mediated epigenetic silencing. The promoter contains multiple binding sites for transcription factors critical to hematopoietic and neuronal development. Key transcriptional regulators of *RASGRP1* include: - **RUNX1 (Runt-related transcription factor 1):** RUNX1 binds to the *RASGRP1* promoter and positively regulates its transcription. Dysregulated RUNX1-mediated transcription of *RASGRP1* has been implicated in the pathogenesis of autoimmunity [6]. In this context, altered RUNX1 binding leads to reduced *RASGRP1* expression, contributing to a breakdown in immune tolerance. - **Gfi1 (Growth Factor Independence 1):** This transcriptional repressor regulates *Rasgrp1* expression in myeloid progenitors. Gfi1 binding to the *Rasgrp1* locus is essential for proper granulocyte colony-stimulating factor (G-CSF) signaling and neutrophil development. Loss of Gfi1 leads to aberrant Rasgrp1 expression and blocks neutrophil differentiation [7]. - **Nurr1 (NR4A2):** This orphan nuclear receptor, critical for dopaminergic neuron maintenance, directly regulates *RASGRP1* expression. Nurr1 binding to the *RASGRP1* promoter suppresses its transcription in microglia, mediating an anti-inflammatory effect in neuroinflammation [8]. - **NKX6-1:** In the context of lens development, NKX6-1 has been identified as a regulator of *Rasgrp1* expression, forming a regulatory module that can partially rescue developmental defects caused by Fgfr2 deficiency [9]. - **H3K27me3 (Histone H3 Lysine 27 Trimethylation):** Epigenetic regulation via Polycomb repressive complex 2 (PRC2)-mediated H3K27me3 deposition at the *RASGRP1* locus silences gene expression. This mechanism is critical in myoblast proliferation and differentiation, where removal of H3K27me3 permits *RASGRP1* expression and promotes myogenic differentiation [10]. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin conformation capture studies (Hi-C) and enhancer prediction algorithms have identified several putative enhancer elements within intronic regions of *RASGRP1* and in the intergenic region between *RASGRP1* and *APTX*. These enhancers are enriched for histone marks H3K4me1 and H3K27ac in T cells and neural progenitor cells, suggesting cell-type-specific regulatory activity. Single-cell multi-omics profiling of human pancreatic islets has identified *RASGRP1* as a target gene for type 1 diabetes (T1D) risk variants, with regulatory elements active in beta cells [1, 11, 12]. This positions *RASGRP1* within the non-coding genetic architecture of T1D susceptibility. ### 1.4 Alternative Splicing and Isoform Diversity Alternative splicing is a major mechanism for generating functional diversity from the *RASGRP1* locus. The most well-characterized splice variant involves the skipping of exon 11, which produces a transcript lacking a portion of the REM domain. This splice variant, termed *RASGRP1Δ11*, encodes a protein with altered catalytic activity and subcellular localization [5]. In T cells from patients with active systemic lupus erythematosus (SLE), reduced expression of the serine/arginine-rich splicing factor 1 (SRSF1) leads to increased inclusion of exon 11 and altered splicing patterns, resulting in reduced overall RasGRP1 protein levels [5]. This splicing dysregulation is a contributing factor to the T cell signaling abnormalities observed in SLE. Other minor splice variants have been detected in various tissues, including variants that skip exons 5 and 6, which encode portions of the C1 domain. The functional consequences of these variants are less well characterized but likely modulate the lipid-binding specificity and membrane recruitment of the protein. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The RASGRP1 protein is a multi-domain signaling scaffold. From the N-terminus to the C-terminus, the domain architecture is as follows: 1. **N-terminal region (aa 1-100):** Contains a disordered region involved in protein-protein interactions. 2. **C1 domain (aa 101-158):** A diacylglycerol (DAG) / phorbol ester-binding domain. This domain is responsible for membrane recruitment in response to DAG production. 3. **EF-hand motifs (aa 159-250):** Two calcium-binding EF-hand motifs. These domains confer calcium sensitivity to the protein. 4. **Ras exchange motif (REM) domain (aa 251-400):** A domain that stabilizes the catalytic machinery and contributes to the overall structural integrity of the GEF. 5. **CDC25 homology domain (aa 401-600):** The catalytic domain responsible for the guanine nucleotide exchange activity on Ras. This domain is homologous to the yeast CDC25 RasGEF. 6. **C-terminal region (aa 601-797):** Contains a proline-rich region and a putative C-terminal tail that may mediate interactions with SH3 domain-containing proteins. ### 2.2 Structural Biology of the Catalytic Core The CDC25 homology domain is the catalytic heart of RASGRP1. Structural studies of homologous RasGEFs, such as SOS1, reveal that this domain adopts an elongated, predominantly alpha-helical fold. The domain interacts with the switch I and switch II regions of Ras, destabilizing the bound GDP and promoting its release. The REM domain, while not directly catalytic, is essential for the proper folding and stability of the CDC25 domain. Mutations in the REM domain, such as the *Rasgrp1*^Anaef^ mouse mutation (E163K in the EF-hand), can have allosteric effects on the catalytic domain, altering the threshold for Ras activation [2]. ### 2.3 Membrane Targeting and the C1 Domain The C1 domain of RASGRP1 is a compact globular domain that binds DAG and phorbol esters with high affinity. The domain consists of two beta-sheets and a short alpha-helix, forming a binding pocket that accommodates the lipid head group. Membrane recruitment via the C1 domain is a critical regulatory step; upon T cell receptor (TCR) stimulation, phospholipase C-γ1 (PLCγ1) generates DAG at the plasma membrane, which recruits RASGRP1 to the membrane where it can access its substrate Ras [3, 4]. The C1 domain also mediates the response to phorbol esters, such as PMA, which are potent activators of RASGRP1 [5]. ### 2.4 Calcium Sensing via EF-hand Motifs The EF-hand motifs are helix-loop-helix structures that coordinate calcium ions. Calcium binding induces a conformational change that is thought to relieve an autoinhibitory interaction, promoting the open, active conformation of RASGRP1. The physiological relevance of calcium sensing is underscored by the *Rasgrp1*^Anaef^ mouse, which harbors a mutation in the first EF-hand (E163K). This mutation impairs calcium binding and results in a gain-of-function phenotype, leading to the accumulation of autoreactive T cells and autoantibody production [2]. ### 2.5 Post-Translational Modifications and Structural Dynamics RASGRP1 is subject to multiple post-translational modifications that regulate its activity and localization. Phosphorylation by protein kinase C (PKC) and other kinases can modulate its GEF activity. Additionally, RASGRP1 itself is prenylated at its C-terminus (farnesylation), which is essential for its membrane association and function. This farnesylation is the target of farnesyltransferase inhibitors (FTIs) like tipifarnib [6, 7]. > **Interactive 3D Protein Visualizer** > > Explore the full three-dimensional architecture of RASGRP1, including the C1 domain, EF-hands, and the catalytic CDC25 domain. > > [**Interactive 3D Protein Visualizer: Load RASGRP1 (PDB: true)**](/tools/protein-structure-viewer?source=alphafold&accession=O95267) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Ras/MAPK Signaling Cascade RASGRP1 is a dedicated activator of the Ras/MAPK pathway. It catalyzes the exchange of GDP for GTP on Ras family GTPases (H-Ras, K-Ras, N-Ras, and R-Ras). Activated Ras-GTP then engages downstream effectors, most notably the Raf/MEK/ERK kinase cascade. This pathway is fundamental to cellular proliferation, differentiation, survival, and apoptosis. ### 3.2 T Cell Receptor (TCR) Signaling The role of RASGRP1 in TCR signaling is the most extensively characterized. Upon TCR engagement, the following cascade occurs: 1. **Lck and ZAP-70 activation:** Src family kinase Lck phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3 complex, recruiting and activating ZAP-70. 2. **Lat and SLP-76 signalosome:** ZAP-70 phosphorylates the adapter protein LAT (linker for activation of T cells), which nucleates a signaling complex including SLP-76, Gads, and PLCγ1. 3. **PLCγ1 activation:** PLCγ1 hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 1,4,5-trisphosphate (IP3) and DAG. 4. **RASGRP1 membrane recruitment:** DAG binds to the C1 domain of RASGRP1, recruiting it to the plasma membrane. Simultaneously, IP3 triggers calcium release from the endoplasmic reticulum, which binds to the EF-hand motifs, further activating RASGRP1. 5. **Ras activation:** Membrane-localized RASGRP1 catalyzes the exchange of GDP for GTP on Ras. 6. **ERK activation:** Ras-GTP activates Raf, which phosphorylates and activates MEK, which in turn phosphorylates and activates ERK1/2. Active ERK translocates to the nucleus and phosphorylates transcription factors such as Elk-1, AP-1, and NF-AT, driving the expression of genes essential for T cell activation, proliferation, and differentiation [3, 4, 8]. A critical feature of RASGRP1 signaling is its role in **basal or tonic signaling**. Even in the absence of strong TCR engagement, a low level of LAT-DAG-RASGRP1 signaling is required to maintain the expression of the TCRα gene and other genes necessary for T cell survival and homeostasis [3]. This basal signaling is essential for the "tonic" signal that allows mature T cells to persist. ### 3.3 B Cell Receptor (BCR) Signaling RASGRP1 is also expressed in B cells, where it plays a role in BCR signaling. BCR engagement leads to the activation of PLCγ2, which generates DAG and recruits RASGRP1 to the membrane. RASGRP1-mediated Ras activation is important for B cell development, particularly at the pre-B cell stage, and for the maintenance of B cell tolerance. *Rasgrp1*-deficient mice exhibit a breach of multiple checkpoints of B cell tolerance, leading to the production of autoantibodies and a lupus-like disease [9, 10, 11]. ### 3.4 Cytokine Receptor Signaling and Hematopoiesis Beyond antigen receptors, RASGRP1 is involved in signaling downstream of cytokine receptors. In T cell acute lymphoblastic leukemia (T-ALL), RASGRP1 overexpression renders the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines such as IL-7 and TSLP [1, 12]. This cytokine-driven signaling promotes leukemic cell survival and proliferation. In myeloid cells, RASGRP1 is a downstream effector of G-CSF receptor signaling. Gfi1 regulates *Rasgrp1* expression to modulate G-CSF signaling, which is essential for granulocyte differentiation [7]. RASGRP1 also plays a role in macrophage proinflammatory responses, where its activation contributes to the pathogenesis of sepsis-induced multiorgan dysfunction [2]. ### 3.5 Receptor Tyrosine Kinase (RTK) Signaling RASGRP1 is not limited to immune cells. It is expressed in epithelial cells, where it modulates signaling from receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor (EGFR). In mammary epithelial cells, Rasgrp1 functions as a dampener of EGFR-Ras-PI3K-AKT signaling. Loss of Rasgrp1 enhances proliferative signaling and enables aberrant EGF-driven branching, indicating that Rasgrp1 sets a threshold for RTK signaling that is critical for coordinated tissue development [3, 4]. ### 3.6 Neuronal Signaling and Dopaminergic Pathways In the central nervous system, RASGRP1 is expressed in the striatum and other brain regions. It interacts with the GTPase Rhes (Ras homolog enriched in striatum) to form a signaling network ("Rhesactome") that regulates motor behavior. RASGRP1 promotes amphetamine-induced motor behavior through this interaction network [5]. Furthermore, RASGRP1 mediates L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease, implicating it in the adverse motor side effects of dopaminergic therapy [6]. Its expression is also altered in the post-mortem brains of schizophrenia patients, linking it to neuropsychiatric pathology [7]. ### 3.7 Protein-Protein Interaction Network RASGRP1 interacts with a diverse array of proteins. Key interactors include: - **Ras GTPases:** The primary substrates. - **14-3-3 proteins:** Bind to phosphorylated RASGRP1 and may regulate its localization. - **SKAP55 (Src kinase-associated phosphoprotein 55):** Binds to RASGRP1 and modulates TCR-induced activation of the Ras-Erk-AP1 pathway [8]. - **Rhes:** A striatal-enriched GTPase that forms a complex with RASGRP1 [5]. - **NCC (sodium-chloride cotransporter):** RASGRP1 signaling leads to NCC ubiquitination and endocytosis, regulating salt transport in the kidney [5, 9, 10]. ```mermaid sequenceDiagram participant TCR as "T Cell Receptor" participant LAT as "LAT Signalosome" participant PLC as "PLCγ1" participant RASGRP1 as "RASGRP1 (Cytosol)" participant RAS as "Ras-GDP (Inactive)" participant RASGTP as "Ras-GTP (Active)" participant RAF as "Raf/MEK/ERK Cascade" participant NUC as "Nucleus (Gene Expression)" TCR->>LAT: Activation & Phosphorylation LAT->>PLC: Recruits & Activates PLCγ1 PLC->>PLC: Hydrolyzes PIP2 to DAG + IP3 PLC-->>RASGRP1: Generates DAG (Membrane Signal) IP3-->>RASGRP1: Triggers Ca2+ Release (EF-hand binding) RASGRP1->>RASGRP1: Translocates to Plasma Membrane (C1 domain) RASGRP1->>RAS: Catalyzes GDP->GTP Exchange RAS->>RASGTP: Conformational Change to Active State RASGTP->>RAF: Recruits & Activates Raf RAF->>RAF: Phosphorylates MEK RAF->>NUC: Phosphorylates ERK, which Translocates to Nucleus NUC->>NUC: Activates Transcription Factors (AP-1, Elk-1) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Loss-of-Function Mutations and Primary Immunodeficiency Biallelic loss-of-function mutations in *RASGRP1* cause a rare form of combined immunodeficiency (CID) characterized by recurrent infections, autoimmunity, and an increased risk of lymphoma. - **Homozygous Nonsense Mutations:** A homozygous nonsense mutation in the catalytic CDC25 domain (e.g., p.Arg519Ter) results in a truncated, non-functional protein. Patients with this mutation present with CID, epidermodysplasia verruciformis (EV), and EBV-positive B cell lymphoma [11]. - **Novel Biallelic Mutations:** Two novel biallelic *RASGRP1* mutations have been identified in patients presenting with immunodeficiency, Hodgkin's lymphoma, and autoimmunity. These mutations impair T cell receptor signaling and lead to defective immune responses [12]. - **ALPS-Like Disease:** A homozygous missense mutation in *RASGRP1* has been identified in a patient with an autoimmune lymphoproliferative syndrome (ALPS)-like phenotype, characterized by lymphadenopathy, splenomegaly, and autoimmune cytopenias [1]. This expands the clinical spectrum of RASGRP1 deficiency to include defects in lymphocyte homeostasis. ### 4.2 Missense Mutations and Autoimmunity The *Rasgrp1*^Anaef^ (E163K) mouse model demonstrates that a single missense mutation in the EF-hand domain can drive a gain-of-function phenotype, leading to the accumulation of CD44^hi^ Helios^+^ T cells, anti-nuclear autoantibodies, and a lupus-like autoimmune disease [2]. This mutation increases basal nucleotide exchange on Ras, lowering the threshold for T cell activation and breaking self-tolerance. In humans, reduced expression of RASGRP1, rather than a specific mutation, is a feature of SLE. This is partly due to altered splicing (increased exon 11 inclusion) driven by reduced SRSF1 expression [5]. Similarly, defective expression of RASGRP1 has been documented in a subset of SLE patients [2]. ### 4.3 Overexpression and Oncogenic Signaling While loss-of-function is linked to immunodeficiency, **overexpression** of RASGRP1 is an oncogenic event in T-ALL. - **T-ALL:** RASGRP1 is frequently overexpressed in T-ALL patient samples. This overexpression increases basal nucleotide exchange on Ras, rendering the Ras/PI3K/Akt pathway responsive to cytokines like IL-7, which promotes leukemic cell growth [1, 12]. Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis, potentially providing a pre-leukemic state [3]. - **Cutaneous Squamous Cell Carcinoma (SCC):** Transgenic mice overexpressing RasGRP1 develop cutaneous SCC in response to skin wounding. This is mediated, in part, by the induction of granulocyte colony-stimulating factor (G-CSF) [4]. - **Breast Cancer:** RASGRP1 is differentially expressed in the lymph nodes of patients with metastatic breast cancer, suggesting a role in tumor dissemination [5]. It is also part of an immune-related gene signature with prognostic value in triple-negative breast cancer [6, 7]. ### 4.4 Genetic Variants and Complex Disease Susceptibility Genome-wide association studies (GWAS) have linked *RASGRP1* variants to susceptibility to several complex diseases: - **Type 1 Diabetes (T1D):** Combined follow-up of GWAS studies identified *RASGRP1* as a T1D susceptibility locus [8]. Single-cell multi-omics studies have confirmed *RASGRP1* as a target gene for T1D-associated regulatory variants in pancreatic islets [1, 11, 12]. - **Type 2 Diabetes (T2D):** Common variants in *RASGRP1* confer risk of type 2 diabetes [9]. A systems genetics approach in human islets also identified *RASGRP1* as a gene associated with T2D [10]. - **Systemic Lupus Erythematosus (SLE):** High-density genotyping in Asian cohorts identified *RASGRP1* as a new SLE risk locus [11]. - **IgA Nephropathy (IgAN):** Novel associations of *RASGRP1* variants have been identified in IgAN [12]. - **Bipolar Disorder:** Fine-mapping of genomic loci has refined *RASGRP1* as a potential risk gene for bipolar disorder [1]. - **Schizophrenia:** Abnormal RASGRP1 expression has been observed in the post-mortem brain and blood serum of schizophrenia patients [7]. ### 4.5 Other Pathogenic Associations - **Rheumatoid Arthritis (RA):** Dysregulation of RASGRP1 and RASGRP3 is observed in RA. The expression of these genes in peripheral B and T cells is modulated by TNFα, and RASGRP3 has been proposed as a biomarker of TNFα inhibitor response [2, 3, 4, 5]. - **Psoriasis:** RASGRP1 influences imiquimod-induced psoriatic inflammation via T cell activation in mice [6]. - **Gastroschisis:** Bioinformatic analysis of gene variants from gastroschisis recurrence identified *RASGRP1* as a potential contributor to the failure of ventral body wall closure [7]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Theileria annulata and Tumor Suppressor Roles *Theileria annulata* is a tick-transmitted apicomplexan parasite that transforms bovine leukocytes into disseminating tumors, causing tropical theileriosis. Comparative transcriptomics revealed that *RASGRP1* is transcriptionally perturbed during Theileria-induced transformation. Functional studies demonstrated that RASGRP1, along with GZMA, has novel tumor suppressor roles in this context. Knockdown of RASGRP1 in Theileria-transformed macrophages and human B lymphoma cells increased their dissemination potential, suggesting that the parasite downregulates RASGRP1 to promote host cell proliferation and spread [8, 9]. ### 5.2 Epstein-Barr Virus (EBV) RASGRP1 deficiency is associated with an inability to control EBV infection, leading to EBV-positive B cell lymphomas [11]. The impaired T cell signaling and defective cytotoxic function in RASGRP1-deficient patients likely compromise immune surveillance of EBV-transformed B cells. ### 5.3 Epidermodysplasia Verruciformis (EV) EV is a rare genetic disorder characterized by increased susceptibility to cutaneous human papillomavirus (HPV) infections. RASGRP1 deficiency has been identified as a cause of EV, highlighting the importance of RASGRP1-mediated T cell immunity in controlling HPV [10, 11]. ### 5.4 SARS-CoV-2 and COVID-19 RASGRP1 expression in peripheral B cells has been linked to the immune response against SARS-CoV-2. Changes in B cell subpopulations are a hallmark of the antiviral response, and RASGRP1 may be a common derangement observed in both rheumatoid arthritis and COVID-19 [11]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Farnesyltransferase Inhibitors (FTIs) RASGRP1 is farnesylated, a lipid modification required for its membrane association and function. Farnesyltransferase inhibitors (FTIs) were developed to target oncogenic Ras, but their efficacy is partly attributed to the inhibition of other farnesylated proteins, including RASGRP1 [6, 7]. - **Tipifarnib (R115777):** This FTI has been extensively studied in AML. A 2-gene classifier based on the *RASGRP1:APTX* expression ratio was shown to predict response to tipifarnib in elderly patients with newly diagnosed AML [2, 3, 4, 12]. A multi-institutional phase 2 trial of tipifarnib plus etoposide demonstrated that the *RASGRP1:APTX* ratio enriches for responders [1]. However, subsequent studies have questioned the robustness of this biomarker [2]. Tipifarnib has also been tested in mantle cell lymphoma, where response prediction remains an area of active investigation [3]. ### 6.2 Natural Compounds - **Catechin Hydrate:** This natural flavonoid has been shown to target macrophagic RASGRP1, ameliorating sepsis-induced multiorgan dysfunction in preclinical models. Catechin hydrate appears to inhibit RASGRP1-mediated proinflammatory signaling in macrophages [2]. ### 6.3 Investigational Approaches - **Gene Therapy:** For patients with loss-of-function *RASGRP1* mutations causing CID, hematopoietic stem cell transplantation (HSCT) is the current standard of care. Gene therapy approaches, involving the introduction of a functional *RASGRP1* gene into autologous hematopoietic stem cells, are theoretically feasible but remain in early preclinical development. - **Targeting RASGRP1 in T-ALL:** Given that RASGRP1 overexpression drives T-ALL, strategies to inhibit its expression or activity are being explored. This could involve RNA interference (RNAi), antisense oligonucleotides (ASOs), or small molecules that disrupt the RASGRP1-Ras interaction. However, no specific small-molecule inhibitors of RASGRP1 have yet entered clinical trials. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Identifier** | **URL** | | :--- | :--- | :--- | | **NCBI Gene** | 10125 | [https://www.ncbi.nlm.nih.gov/gene/10125](https://www.ncbi.nlm.nih.gov/gene/10125) | | **Ensembl** | ENSG00000159674 | [https://useast.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159674](https://useast.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159674) | | **UniProt** | O95267 | [https://www.uniprot.org/uniprotkb/O95267/entry](https://www.uniprot.org/uniprotkb/O95267/entry) | | **RCSB PDB** | Multiple (e.g., 2R3P for C1 domain) | [https://www.rcsb.org/](https://www.rcsb.org/) | | **OMIM** | 603062 | [https://www.omim.org/entry/603062](https://www.omim.org/entry/603062) | | **ClinVar** | Gene: RASGRP1 | [https://www.ncbi.nlm.nih.gov/clinvar/?term=RASGRP1%5Bgene%5D](https://www.ncbi.nlm.nih.gov/clinvar/?term=RASGRP1%5Bgene%5D) | | **STRING** | O95267 | [https://string-db.org/network/9606.ENSP00000301063](https://string-db.org/network/9606.ENSP00000301063) | | **BioGRID** | 112590 | [https://thebiogrid.org/112590](https://thebiogrid.org/112590) | | **Gene Ontology (GO)** | GO:0005085 (guanyl-nucleotide exchange factor activity) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) | --- ## Related Clinical & Scientific Guides * [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway) * [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway) * [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway) ## References [1] "RASGRP1 Gene" - (2020). Definitions. URL: https://www.semanticscholar.org/paper/5375eb5cb4442b8f9464c6520846506221652544 [2] Jun-yan Li, F. Tao, Xinxing Wu, Ying-Zi Tan, L. He, Hao Lu (2015). "Common RASGRP1 Gene Variants That Confer Risk of Type 2 Diabetes". Genetic Testing and Molecular Biomarkers. URL: https://www.semanticscholar.org/paper/ff2d9aa8c9a6b6c598e0db6c9bd207f46d68e386 [3] L. Burrows (2018). "Variation in ovine RAS Guanyl Releasing Protein 1 (RASGRP1) gene and its association with flystrike in New Zealand sheep". Scientific Publication. URL: https://www.semanticscholar.org/paper/84601905717b38d1519cf2ccc646bd544b9c349c [4] Liyao Xiao, Jiaxin Qiao, Yiyang Huang, Baohua Tan, L. Hong, Zicong Li, Gengyuan Cai, Zhenfang Wu, E. Zheng, Shanshan Wang, Ting Gu (2024). "RASGRP1 targeted by H3K27me3 regulates myoblast proliferation and differentiation in mice and pigs". Acta Biochimica et Biophysica Sinica. URL: https://www.semanticscholar.org/paper/efa38e044b10ccb0b6f0dd4cc0a0e9a9094a4451 [5] Yiwen Mao, Huiyao Ge, Weiwei Chen, Yirui Wang, H. Liu, Zhuo Li, Yu Bai, Daiyue Wang, Yafen Yu, Q. Zhen, Bao Li, Lian-hua Sun (2023). "RasGRP1 influences imiquimod-induced psoriatic inflammation via T-cell activation in mice." International Immunopharmacology. URL: https://www.semanticscholar.org/paper/d95145b7f714c91db6e63821773011aca225f43f [6] Arianna De Rosa, A. di Maio, Silvia Torretta, M. Garofalo, Valentina Giorgelli, Rita Masellis, T. Nuzzo, F. Errico, A. Bertolino, S. Subramaniam, A. Rampino, A. Usiello (2022). "Abnormal RasGRP1 Expression in the Post-Mortem Brain and Blood Serum of Schizophrenia Patients". Biomolecules. URL: https://www.semanticscholar.org/paper/cec4d9d98bc76d294f59b0788ad632b8e171db68 [7] M. Momenilandi, A. Pourvali, Leen Nima Greet Isabelle Saba Narges Roya Moens Parvaneh Wuyts Meyts Arshi Rahmanian Sherkat, Leen Moens, N. Parvaneh, G. Wuyts, I. Meyts, S. Arshi, Narges Rahmanian, R. Sherkat, Mohammad Shahrooei, X. Bossuyt (2022). "Two Novel Biallelic RASGRP1 Mutations Presenting with Immunodeficiency, Hodgkin’s Lymphoma, and Autoimmunity". Journal of Clinical Immunology. URL: https://www.semanticscholar.org/paper/5b5f19a9779671cdf30f6c923d5ae43b4cfb0089 [8] Mihee Oh, Sun Young Kim, J. Gil, Jeongsu Byun, Dong-Wook Cha, B. Ku, Woonghee Lee, W. Kim, Kyoung-jin Oh, Eun-Woo Lee, Kwang-Hee Bae, Sang Chul Lee, B. Han (2019). "Nurr1 performs its anti-inflammatory function by regulating RasGRP1 expression in neuro-inflammation". Scientific Reports. URL: https://www.semanticscholar.org/paper/ad6c50075de8858349492a1bc4d55decf769d755 [9] Matthijs J. D. Baars, Thera Douma, Dimitre R. Simeonov, D. Myers, Saikat Banerjee, Kayla R. Kulhanek, Susan Zwakenberg, Marijke P. A. Baltissen, S. de Roock, F. van Wijk, M. Vermeulen, A. Marson, J. Roose, Y. Vercoulen (2019). "Dysregulated RASGRP1 expression through RUNX1 mediated transcription promotes autoimmunity". bioRxiv. URL: https://www.semanticscholar.org/paper/eee8ac9f9646958204fbc2b3b2db93d8fd01e77c [10] S. Uhrig, Julia Ellermann, T. Walther, Pauline Burkhardt, M. Fröhlich, B. Hutter, U. Toprak, O. Neumann, A. Stenzinger, C. Scholl, S. Fröhling, B. Brors (2021). "Accurate and efficient detection of gene fusions from RNA sequencing data". Genome Research. URL: https://www.semanticscholar.org/paper/891db906478a188785f79a9a9239e12f205de513 [11] Evan Markegard, Evan Trager, Chih-wen Ou Yang, Weiguo Zhang, A. Weiss, J. Roose (2011). "Basal LAT-diacylglycerol-RasGRP1 Signals in T Cells Maintain TCRα Gene Expression". PLoS ONE. URL: https://www.semanticscholar.org/paper/49ee9f437b1d55248c6673e0579b3193e9c3a1fe [12] M. Raponi, T. Vener, C. Derecho, J. Greer, S. Malek, J. Palma, J. Karp (2009). "RASGRP